Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 14/20 | 0.44 |
| ▸ | PI4KA | P42356 | 2/20 | 0.42 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.42 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.42 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.42 |
| ▸ | RET | P07949 | 1/20 | 0.42 |
| ▸ | XDH | P47989 | 1/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.42 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.39 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4184377 | 0.78 | ENPP1 (0.43) | ENPP1ENPP3PDE3BPDE3A | |
| SCHEMBL2015028 | 0.78 | PDE3B (0.53) | ENPP1ENPP3PDE3BPDE3A | |
| SCHEMBL30556397 | 0.76 | ENPP1 (0.42) | ENPP1ENPP3PDE3BPDE3A | |
| SCHEMBL24671871 | 0.76 | ENPP1 (0.42) | ENPP1ENPP3PDE3BPDE3A | |
| SCHEMBL5436041 | 0.74 | DCPS (0.38) | PDE3BPDE3A | |
| SCHEMBL12775783 | 0.74 | PDE3B (0.57) | ENPP1ENPP3PDE3BPDE3A | |
| SCHEMBL12776683 | 0.73 | PDE3B (0.58) | ENPP1ENPP3PDE3BPDE3A | |
| SCHEMBL12776514 | 0.71 | ENPP1 (0.41) | ENPP1ENPP3PDE3BPDE3A | |
| SCHEMBL10377596 | 0.71 | PDE3B (0.62) | PDE3BPDE3A | |
| SCHEMBL13199870 | 0.69 | PDE3B (0.48) | ENPP1PI4KAPI4K2BPI4K2API4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4620531-A2 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | Revolution Medicines, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| US-12258366-B2 | Bicyclic heteroaryl compounds and uses thereof | Revolution Medicines, Inc. (US) | 2025-03-25 | — | — | US | disclosed |
| US-20230365605-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-11-16 | — | — | US | disclosed |
| CN-116425742-A | Bicyclic heteroaryl compounds and uses thereof | 锐新医药公司 | 2023-07-14 | — | — | CN | disclosed |
| EP-4055017-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | Revolution Medicines, Inc. (US) | 2022-09-14 | — | — | EP | disclosed |
| CN-114901662-A | Bicyclic heteroaryl compounds and uses thereof | 锐新医药公司 | 2022-08-12 | — | — | CN | disclosed |
| US-11168102-B1 | Bicyclic heteroaryl compounds and uses thereof | Revolution Medicines, Inc. (US) | 2021-11-09 | — | — | US | disclosed |
| US-20210139517-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | Revolution Medicines, Inc. | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11168102-B1 | Bicyclic heteroaryl compounds and uses thereof | SOS1, SOST, SOS2 | ENPP1 142/4885PI4KA 2059/4885PI4K2B 1646/4885 |
| US-20230365605-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | SOST, SOS1, SOS2 | ENPP1 62/4885PI4KA 1414/4885PI4K2B 1152/4885 |
| US-20210139517-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | SOST, SOS1, SOS2 | ENPP1 62/4885PI4KA 1414/4885PI4K2B 1152/4885 |
| US-12258366-B2 | Bicyclic heteroaryl compounds and uses thereof | SOST, SOS1, SOS2 | ENPP1 62/4885PI4KA 1414/4885PI4K2B 1152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.